Compare
Gilead Sciences vs Regeneron Pharmaceuticals (GILD vs REGN)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Gilead Sciences (GILD) returned +36.1% and Regeneron Pharmaceuticals (REGN) +40.4%; so far this year the figures are +36.0% and +17.2%.
Gilead Sciences is the larger company by market value, about 2.2 times the size of Regeneron Pharmaceuticals.
Revenue grew +6.5% at GILD and +18.6% at REGN over the last year.
GILD yields 1.95%. REGN yields 0.41%.
Data as of the latest close. Not investment advice.
Relative performance
| GILD | REGN | |
|---|---|---|
| Price | $166.89 | $904.35 |
| 1-day | -0.41% | +0.16% |
| YTD | +35.97% | +17.16% |
| 1 year | +36.15% | +40.39% |
| 3 years | +108.12% | +14.29% |
| Market cap | $207.0B | $95.5B |
| P/E | — | 20.0 |
| P/S | 6.68 | 5.65 |
| P/B | 15.87 | 2.85 |
| Revenue growth | +6.50% | +18.60% |
| EPS growth | -149.00% | +8.30% |
| Gross margin % | 79.9 | 36.4 |
| Net margin % | -12.5 | 28.5 |
| ROE % | -29.6 | 14.4 |
| Debt / equity | 2.01 | 0.10 |
| FCF yield % | 6.7 | 4.0 |
| Dividend yield % | 1.95 | 0.41 |
| Beta | 0.37 | 0.29 |
| RSI (14) | 60.2 | 63.1 |
| Technical rating |